2013 American Society of Clinical Oncology Abstracts

2013 ASCO Abstracts from Myeloma Institute Faculty:

Factors that predict successful remobilization after autologous hematopoietic progenitor cell transplant (aHCT) for multiple myeloma.http://meetinglibrary.asco.org/content/117841-132

Cure candidates: Characteristics of >10yr progression-free survivors (PFS-10) and continuous CR (CCR-10) after total therapy 1 and 2 (TT1, TT2) for multiple myeloma (MM).http://meetinglibrary.asco.org/content/117697-132

Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM). http://meetinglibrary.asco.org/content/114116-132

Total therapy 5 (TT5) for newly diagnosed high-risk multiple myeloma (HRMM): Comparison with predecessor trials total therapy 3a and 3b (TT3 a/b). http://meetinglibrary.asco.org/content/118187-132